巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Aeterna Zentaris

AEZS
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Aeterna Zentaris - 延遲價格・最後更新於 20/01 22:00
最高位
--
最低位
--
開市價
--
前收市價
0.352
成交量(千)
--
成交額(百萬)
--
買入
--
賣出
--
每手股數
--
市值(百萬)
42.74
市盈率
--
息率
--
差價
--
52週高低
3.620 - 0.333
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Aeterna Zentaris
證券代碼
AEZS.US
所屬板塊
Biotechnology
公司業務
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company is actively pursuing opportunities to commercialize macimorelin in the EU & the rest of the world.
發行量
121397007
公司總部
315 Sigma Drive, Suite 302D
公司網址
https://www.zentaris.com
公司電郵
IR@aezsinc.com
公司電話
+1 843 900-3223
暫無內容

關於

Aeterna Zentaris(AEZS.US)所屬的行業板塊為Biotechnology。
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company is actively pursuing opportunities to commercialize macimorelin in the EU & the rest of the world.
詳細公司背景可參考: https://www.zentaris.com